Compare Eli Lilly And Co (LLY) vs RLX Technology Inc (RLX) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

RLX trades at $2.06, up 0.49% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 revenue growth driven by international expansion, with 2025 revenue of $3.62B and net income of $921.87M. Recent news highlights the vaping industry's projected growth and RLX's cash-rich, debt-free balance sheet.

Outlook is mixed: strong fundamentals and industry tailwinds support growth, but recent EPS misses and a single analyst 'Hold' rating suggest caution. Key risks include regulatory scrutiny and execution challenges in global markets. The stock presents opportunity for long-term investors if expansion succeeds.